Longeveron Reports Positive Top-Line Phase 2a Clinical Trial Results for Lomecel-B

DENVER, Colo., Oct 5, 2023 ( Longeveron Inc. (NASDAQ: LGVN) reported, this morning, positive top-line results from its Lomecel-B, its investigational product, Phase 2a trial for the treatment of mild Alzheimer’s disease. The Company is hosting a conference call and webcast today at 8:00 AM ET to discuss the results, which includes primary safety endpoint met across all study groups, with additional biomarker data expected to be announced in the coming weeks

Longeveron is trading at $2.64, up $0.13 (+5.18%), on 5.95M premarket shares traded.

Its 52-week range is $2.12 to $4.5793. It bounced off of its 52-week low, a few weeks ago, and hit a high of $3.85, two minutes after the announcement. Its next key resistance is $3.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist